Probiotic Ocular Compositions for Non-Invasive Lesion Resolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular diseases and inflammatory lesions of ocular adnexa, such as dry eyes, eyelid allergy, conjunctivitis, blepharitis, meibonite, dacryoliths, and stye, are either ineffective or risky, with non-invasive methods failing to provide complete resolution and invasive methods posing complications, especially in pediatric patients.
Innovation Solution
A mixture or composition comprising probiotic bacterial strains, including Streptococcus thermophilus ST10, Lactococcus lactis LLC02, and Lactobacillus delbruecki subsp. bulgaricus LDB 01, administered orally or topically, to treat these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If non-invasive conservative methods are used for treatment, then the rate of complications is minimized, but the effectiveness in total resolution of inflammatory diseases and lesions is insufficient and recurrence occurs
Solution Approach 1:
The patent introduces probiotic bacteria as an intermediary therapeutic agent that mediates between conservative treatment safety and invasive treatment effectiveness. The probiotics act as a biological mediator that can resolve inflammatory lesions through immunomodulation and direct antimicrobial effects, bridging the gap between non-invasive safety and effective resolution.
Solution Approach 2:
The patent changes the therapeutic parameter from conventional antibiotics and anti-inflammatories to probiotic bacteria with specific immunomodulatory properties. This parameter change allows the treatment to maintain the safety profile of conservative methods while achieving the effectiveness previously only attainable through invasive procedures.
2Reliability
If invasive methods such as intralesional steroid injection or surgical incision are performed, then complete resolution of lesions is achieved, but complications and side effects increase
Solution Approach 1:
The patent converts the harmful presence of pathogenic bacteria into a beneficial therapeutic mechanism by introducing probiotic bacteria that outcompete pathogens for resources and space. The probiotics benefit from the same ecological niche as pathogens but produce beneficial effects through competitive exclusion and immunomodulation, avoiding the harmful side effects of invasive treatments.
Solution Approach 2:
The probiotic bacteria perform self-service by autonomously colonizing the lesion site, producing antimicrobial substances, and modulating the local immune response without requiring surgical intervention. The treatment system serves itself through the self-proliferating and self-acting nature of the probiotic organisms.
3Reliability
If surgery is performed on pediatric patients under three years of age, then inflammatory lesions can be resolved, but risks related to full body anaesthesia and parental acceptance decrease
Solution Approach 1:
The patent employs a temporary, non-invasive probiotic treatment that acts as a short-term therapeutic intervention without the long-term risks of surgery and anaesthesia. The probiotics serve as a temporary placeholder therapy that resolves lesions without creating permanent structural changes or requiring general anaesthesia in pediatric patients.
Data Source
AI summary
The present invention relates to mixtures, or compositions comprising said mixtures, comprising at least one bacterial strain, preferably at least one probiotic bacterial strain or a derivative thereof, as well as to the use of said mixtures or compositions in methods for the preventive and/or curative treatment of an inflammatory ocular and/or periocular lesion, preferably in methods for the treatment of ocular diseases such as dry eyes, eyelid allergy, conjunctivitis, blepharitis, meibonite, dacryoliths, stye, inflammatory lesions of ocular adnexa and associated symptoms.